Ovarian cancer

This trial is testing an experimental oral drug, LG00313112, in people with advanced solid tumors that carry a specific genetic change called TP53 Y220C. The drug aims to restore the function of the p53 protein, which normally helps stop cancer growth. The study includes adults w…

This trial is testing whether a personalized cell therapy can help women with ovarian cancer that has returned. Doctors will remove a tumor, extract immune cells called tumor-infiltrating lymphocytes (TILs), and boost them in the lab before infusing them back into the patient. Af…

This trial is testing whether a targeted therapy called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. Participants have already completed first-line platinum-…

Researchers are testing a combination of three oral drugs, imlunestrant, abemaciclib, and selinexor, in people with low grade serous ovarian cancer or endometrioid endometrial cancer. The trial enrolls 60 participants in two separate groups, one for each cancer type. Everyone rec…

Researchers are testing whether torvutatug samrotecan, alone or with bevacizumab, works better than standard care as maintenance therapy for people with platinum-sensitive relapsed ovarian, fallopian tube, or primary peritoneal cancer. The trial enrolls about 600 participants who…

This trial is testing whether a new drug called raludotatug deruxtecan (R-DXd), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer and delay cancer growth compared to standard chemotherapy. The study includes adults with high-grade serous or…

Researchers are studying whether adding daily atorvastatin to standard chemotherapy and surgery changes the immune cells inside advanced high grade serous tumors of the ovary, fallopian tube, or peritoneum. The trial enrolls 40 adults with Stage III or IV disease who cannot have …

Researchers are testing a new drug called TS-104 in adults with advanced solid tumors, including lung, head and neck, ovarian, endometrial, esophageal, and gastric cancers. TS-104 is a peptide drug conjugate: it uses a targeting peptide to carry the chemotherapy drug MMAE directl…

Researchers are testing an investigational oral drug called catequentinib hydrochloride (AL3818) in adults with advanced or metastatic endometrial cancer, low grade serous ovarian cancer, soft tissue sarcoma, or glioblastoma. The trial has two parts: a phase 1b part to find safe …

This trial tests whether adding an experimental drug called INCB123667 to the standard maintenance therapy bevacizumab can delay cancer recurrence in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants must have completed initial chemotherapy …

This early-stage trial tests an investigational drug called ABBV-253 in adults with advanced solid tumors, including lung, colorectal, and pancreatic cancers. The study aims to find safe doses and see whether the drug can shrink tumors. Participants receive the drug by infusion, …

This phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returne…

This trial tests whether raludotatug deruxtecan, given alone or with bevacizumab, can delay cancer growth better than standard care in people with platinum-sensitive ovarian, primary peritoneal, or fallopian tube cancer that has returned after first treatment. About 600 adults as…

This phase II trial is testing an investigational drug called BL-M09D1 in people with advanced gynecological cancers (such as ovarian, cervical, or endometrial cancer) and other solid tumors that have progressed despite standard treatment. The drug is given by intravenous infusio…

This early-stage trial is testing an experimental drug called LAE118 in people with advanced solid tumors that have a specific genetic change (PIK3CA mutation). The study will evaluate the drug's safety and tolerability when given alone or combined with other anti-cancer medicati…

This early-stage trial is testing whether combining two chemotherapy drugs—liposomal irinotecan and cisplatin—can safely shrink or control advanced solid tumors that have not responded to standard treatments. The study will enroll about 44 adults aged 20 to 85 with various types …

This trial is testing whether adding trastuzumab to the standard maintenance drug bevacizumab can delay cancer progression in people with advanced ovarian, fallopian tube, or primary peritoneal cancer. Participants who have completed initial chemotherapy plus bevacizumab without …

This early-stage trial is testing an investigational drug called TJ102 in people with advanced or metastatic ovarian cancer and other solid tumors that have stopped responding to standard treatments. TJ102 is a type of targeted therapy called an antibody-drug conjugate, designed …

This phase II trial is testing whether a new drug, trastuzumab rezetecan, combined with carboplatin (and sometimes bevacizumab) can help people with platinum-sensitive recurrent ovarian cancer. Participants will be randomly assigned to receive either this experimental combination…

This study tests whether giving a dye called Cytalux a few days before surgery works as well as giving it closer to the operation. The dye makes tumors glow under a special light, helping surgeons remove them more completely. About 106 adults with suspected lung cancer or confirm…

This phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a ho…

This study offers continued access to an experimental combination of two oral drugs—avutometinib and defactinib—for people with recurrent low-grade serous ovarian cancer (LGSOC) who have already been benefiting from this treatment in a prior study. The goal is to allow uninterrup…

This study tracks the safety and effectiveness of mirvetuximab soravtansine (MIRV), a drug that targets a protein called folate receptor alpha on cancer cells, in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer. Researchers will observe 400 patients r…

This phase 1 trial tests an experimental drug called TJ037130 in adults with advanced solid tumors, including ovarian, gastric, and endometrial cancers that have spread. The main goal is to check the drug's safety and find the best dose for future studies. Participants receive TJ…

This study tests a new biologic drug called XYA02 in 190 adults with advanced solid tumors (including lung, ovarian, and pancreatic cancers) that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumo…

This study tests a new drug, ubamatamab, combined with standard chemotherapy drugs (carboplatin, paclitaxel, and bevacizumab) in 43 people with advanced ovarian cancer that did not respond well to initial treatment. The goal is to see if the combination is safe and can shrink tum…

This study tests an experimental drug, TAX2, in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in more people. Researchers will monitor side effects, h…

This trial tests a drug called sacituzumab govitecan in people with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer that has high levels of a protein called TROP-2. Participants must have already tried standard treatments without success. The drug is g…

This phase 2 trial tests whether combining two immunotherapy drugs (iparomlimab and tuvonralimab) with standard chemotherapy before surgery can improve outcomes for people with advanced ovarian cancer. Participants receive 3-4 cycles of the combination, followed by surgery to rem…

This study tests whether a combination of two immunotherapy drugs (QL1706), a targeted therapy (bevacizumab), and standard chemotherapy can shrink advanced ovarian cancer before surgery. About 36 women with stage III-IV ovarian cancer will receive the treatment every 3 weeks, the…

This study tests a new oral drug called DAT-2645 in up to 30 people with advanced or metastatic ovarian cancer that has a BRCA1/2 mutation or is HRD-positive. Participants take the drug daily in 21-day cycles. The main goal is to see if the drug shrinks tumors, and researchers wi…

This early-phase trial tests a one-time treatment called OPB-201, where a patient's own immune cells are modified in a lab to better recognize and attack cancer cells that carry a protein called PRAME. The study will enroll 30 adults with recurrent endometrial cancer or platinum-…

This early-phase trial tests a new cell therapy called NK521 for people with advanced liver cancer (hepatocellular carcinoma) or ovarian cancer that has not responded to standard treatments. NK521 are natural killer (NK) cells that have been gene-edited to remove three proteins t…

This trial tests whether fluzoparib plus bevacizumab works as well as the standard olaparib plus bevacizumab for maintenance therapy in women with HRD-positive advanced ovarian cancer after initial chemotherapy. The study enrolls about 120 participants and tracks how long they st…

This phase 2 trial is testing a new, intensive treatment plan for 28 people with advanced ovarian cancer. The approach combines chemotherapy given into the abdomen and vein, a special vaccine made from the patient's own immune cells, and the immunotherapy drug Keytruda. The goal …

This early-phase study tests a drug called zanidatamab in 10 adults with advanced HER2-positive solid tumors (like endometrial, bladder, or pancreatic cancer) that have worsened after at least one prior treatment. Participants receive the drug by IV every two weeks. The main goal…

This study tests a combination of two drugs, liposomal irinotecan and enlonstobart, in 30 women with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if the combo can shrink tumors and delay cancer growth. Participants receive treatment every tw…

This study will observe 500 women with ovarian, fallopian tube, or primary peritoneal cancer who are taking the drug senaparib. Researchers will track side effects and how well the drug controls the cancer in real-world conditions, outside of a strict clinical trial. The goal is …

This study tests whether adding losartan, a blood pressure medication, to weekly paclitaxel chemotherapy can shrink tumors in people with ovarian cancer that no longer responds to platinum-based drugs. About 27 adults with advanced ovarian, fallopian tube, or primary peritoneal c…

This study tests whether a traditional Chinese herbal formula (Tiaoshen Anti-cancer granules) combined with cognitive behavioral therapy for insomnia (CBT-I) can improve sleep and possibly extend survival in 360 women with advanced ovarian cancer. Participants will receive either…

This early-stage study tests two drugs, CKD-215 and D215, in 24 adults aged 19-75 with advanced BRCA-mutated ovarian, fallopian tube, or primary peritoneal cancer. The goal is to compare how the body processes each drug and check for side effects. Participants will receive both d…

This study tests a combination of three drugs (Benmelstobart, Anlotinib, and low-dose Cyclophosphamide) in 40 women whose ovarian, fallopian tube, or peritoneal cancer has come back. The goal is to see if this mix can keep the cancer from growing for longer. Participants must be …

This phase 2 trial tests whether a peptide vaccine (NY-ESO-1) combined with an immunotherapy drug (toripalimab-tpzi) can prevent resistance to treatment in 24 women with stage III/IV ovarian cancer that no longer responds to platinum chemotherapy. The vaccine primes the immune sy…

This early study tests a personalized vaccine (YS247) made from a patient's own immune cells to fight a specific type of ovarian cancer (HRD-negative). Only 9 women who haven't been cured by standard therapy will take part. The main goal is to check safety, not yet to prove it wo…

This early-phase trial is testing an experimental drug called WSK-IM02 in 36 women with platinum-resistant recurrent ovarian cancer, a type that no longer responds to standard platinum chemotherapy. The drug is given as an injection into the abdomen. The main goal is to check saf…

This study tests an experimental drug called QLS5132, given with other cancer treatments, for people with advanced solid tumors like stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination shrinks tumors. About 626 participants w…

This study tests a new drug combination for women with recurrent ovarian cancer that still responds to platinum chemotherapy. The treatment includes an immunotherapy (iparomlimab/tuvonralimab) plus standard chemo, followed by a maintenance drug (olaparib). The goal is to see if t…

This study tests a combination of two drugs—CVL237 tablets and serplulimab injection—in people with advanced solid tumors that have lost or have low levels of a protein called PTEN. The trial aims to find the safest dose and see if the combo can shrink tumors or delay their growt…

This early-stage study tests a new treatment for people with advanced ovarian cancer or other solid tumors that have come back or not responded to standard therapy. The treatment uses a patient's own immune cells that are genetically modified to better recognize and attack cancer…

This early-phase study tests a new cell therapy called KT032 in 24 adults with advanced solid tumors (ovarian, mesothelioma, colon cancer) that have spread to the abdomen and haven't responded to standard treatments. The main goal is to check safety and find the best dose, while …

This study tests a daily pill called hetrombopag to see if it can safely raise low platelet counts in women with gynecological cancers (like ovarian or cervical cancer) after chemotherapy. About 244 women whose platelets dropped too low will take the drug to help them complete th…

This Phase 2 trial will test a combination of the experimental drug QL1706 with standard chemotherapy or with olaparib and intraperitoneal chemotherapy as a pre-surgery treatment for 50 women with advanced ovarian cancer. The goal is to see if this approach can shrink tumors enou…

This study compares a single chemotherapy drug (paclitaxel) to the standard two-drug combo (paclitaxel plus carboplatin) as initial treatment before surgery for advanced ovarian cancer. It is for patients whose tumors have high levels of a protein called PARK2, which may make the…

This study looks at whether a blood test score (KELIM) can help doctors decide the best time for surgery in people with advanced ovarian cancer. After three rounds of chemotherapy, those with a good score will have surgery right away, while those with a poor score will get more c…

This study tests whether a combination of two drugs (fluzoparib and famitinib) can help keep advanced ovarian cancer from returning after successful initial chemotherapy. About 43 women with stage III-IV ovarian cancer who responded to platinum-based chemo will take these pills d…

This Phase 2 trial tests a new drug called JPI-547 combined with bevacizumab in 81 women with relapsed ovarian cancer who have already been treated with PARP inhibitors and responded to platinum chemotherapy. The study aims to find the best dose and see if the combination helps k…

This phase 2 trial tests two oral drugs, zeprumetostat and fuzuloparib, in 30 people with advanced or recurrent ovarian cancer who do not have BRCA gene mutations. The goal is to see if the combination can shrink tumors and delay progression. Participants first take fuzuloparib a…

This study tests two drug combinations (fluzoparib plus famitinib or fluzoparib plus SHR-1701) given before surgery to shrink advanced ovarian cancer in 104 women whose tumors cannot be fully removed right away. The goal is to see how well these treatments work and how safe they …

This study tests an experimental pill called ZL-85FA in people with advanced solid tumors (breast, ovarian, fallopian tube, primary peritoneal, or prostate cancer) that have not responded to standard treatments. The trial has two phases: first, finding a safe dose, then checking …

This study looks at whether a second surgery to remove visible tumors (secondary cytoreductive surgery) after chemotherapy helps women with platinum-sensitive recurrent ovarian cancer. About 160 participants will be randomly assigned to get surgery plus chemo or chemo alone. The …

This study tests a method called PIPAC, where the chemotherapy drug paclitaxel is turned into a pressurized spray and delivered directly into the abdomen. It is for women with ovarian cancer that has come back and no longer responds to platinum-based chemotherapy. The trial has t…

This phase 2 trial tests a combination of three drugs—liposomal irinotecan, sintilimab, and anlotinib—in 36 people with recurrent or persistent ovarian clear cell carcinoma. The goal is to see if the treatment can shrink tumors and control the disease. Participants must have alre…

This study tests a minimally invasive procedure that uses heat (radiofrequency or microwave) to destroy abnormal growths in the abdominal wall, such as cancer spread, desmoid tumors, or endometriosis. It involves 30 people who cannot have surgery or choose not to. The goal is to …

This study tests whether using an AI tool to analyze a patient's body composition from a CT scan can help doctors personalize chemotherapy dosing. The goal is to reduce severe side effects like low white blood cell counts in women with endometrial or ovarian cancer. About 294 par…

This study tests a drug called sacituzumab in 22 people with a rare and aggressive type of ovarian cancer (clear cell carcinoma) that has worsened after immunotherapy. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The main goal is to see how man…

This is the first human study of an experimental cancer drug called M7437, which targets a specific protein found on certain tumor cells. The study will test the safety, side effects, and early effectiveness of M7437 in 138 people with advanced solid tumors that have stopped resp…

Researchers are testing a new PET/CT imaging tracer called [68Ga]-LY4257529 that targets a protein called GRPR, which some cancers make in large amounts. The study includes up to 60 adults with breast cancer or other tumors known or suspected to express GRPR, such as prostate, ov…

Researchers are testing a new imaging agent called 111In-TJD-31 that targets placental alkaline phosphatase (ALPP), a protein found on many solid tumor cells but rarely in healthy adult tissue. The study enrolls 8 participants: 2 healthy volunteers who give blood samples and 6 pa…

Many cancer trials require patients to have specific molecular markers, so researchers test large numbers of people to find the few who qualify. This study evaluates FATHOM, an AI system that reads clinical trial records and routine tumor slides to predict which patients carry th…

This study is looking at whether a blood test called Galleri can help detect ovarian cancer early in people with BRCA1 or BRCA2 gene changes, who are at higher risk. Participants will give a blood sample and answer questionnaires about their experience. The study will also check …

This study tests whether machine learning can analyze ultrasound images to distinguish benign from malignant adnexal masses, growths near the ovaries that are common but hard to classify. Researchers will develop and validate AI models using images from 12,000 patients across mul…

This trial is testing two new imaging tracers, called CM500, to see if they can help detect solid tumors anywhere in the body. The tracers are given by injection and then used with PET scans to create detailed images. The study includes healthy volunteers and people with various …

This trial tests a new PET/CT tracer called 89Zr-DFO-Mirvetuximab, which targets a protein (FRα) found on many ovarian cancer cells. Researchers will give the tracer to 20 people with advanced or recurrent ovarian cancer and take scans at several time points. They will compare th…

This trial is testing whether a breath analysis device can detect unique chemical patterns—called volatile organic compounds—that may signal the presence of cancer. Researchers will collect breath samples from 1,000 people with various cancers and 1,000 healthy volunteers, then u…

This study tests a new imaging technique that could help surgeons see if cancer has spread to lymph nodes during surgery for gynecologic cancers like ovarian, endometrial, cervical, and vulvar cancer. The method uses a special microscope to examine lymph node tissue right after i…

This study evaluates several experimental blood tests designed to detect ovarian cancer earlier. Researchers compare results from people with ovarian cancer to those without cancer to see how well the tests distinguish between the two. The tests look for specific changes in the b…

This study looks at whether a specialized blood test can detect tiny bits of cancer DNA in the blood of women with advanced ovarian cancer after they finish initial treatment. Researchers will follow 300 women for up to 3 years, taking blood samples at key times. The goal is to s…

This study tests a new radioactive tracer called 68Ga-FAPI-PSMA for PET/CT scans to see if it can find and stage solid tumors (like prostate, liver, and ovarian cancers) better than current tracers. About 20 adults with suspected or confirmed tumors will receive the tracer and ha…

This study will test a new blood test that looks for DNA changes to detect ovarian cancer, especially in early stages. Researchers will compare test results from 1,000 women with and without ovarian cancer to see how accurate it is. If it works well, it could lead to a simple scr…

This study is testing a new medical device that gently collects cells from the vagina to look for signs of ovarian and endometrial cancers. The goal is to see if this less invasive method can accurately detect these cancers compared to standard tests. About 300 women, some with c…

This study tests whether artificial intelligence (AI) can predict the type of ovarian cancer and how well surgery might work by analyzing videos from a diagnostic laparoscopy. Researchers will collect videos from 100 women with advanced ovarian cancer and train an AI to recognize…

This study compares a new DNA sequencing platform (MGI) against the current standard (Illumina) for diagnosing hereditary cancers like breast and ovarian cancer, Lynch syndrome, and intestinal polyposis. Researchers will analyze 248 patient samples using both platforms to see if …

This study tests a new blood test called OCS that uses exosome technology to monitor for ovarian cancer recurrence. It focuses on patients whose CA125 levels were normal before initial treatment, making standard monitoring difficult. The trial will enroll 32 women with stage I-IV…

This study tests whether it is practical and safe to remove the fallopian tubes during planned weight-loss (bariatric) surgery as a way to lower the risk of ovarian cancer. Many ovarian cancers are thought to start in the fallopian tubes, and removing them can reduce risk by abou…

This study tests whether electroacupuncture (using mild electric pulses on needles) plus tiny thumbtack needles can prevent nerve damage caused by chemotherapy in people with early-stage cancer. About 278 patients with breast, stomach, bowel, lung, or ovarian cancer will receive …

This study tests whether electroacupuncture (acupuncture with mild electrical pulses) combined with tiny thumbtack needles can prevent peripheral neuropathy—numbness, tingling, or pain—caused by chemotherapy in people with advanced cancer. The trial enrolls adults with stage IV b…

This study tests whether removing the fallopian tubes at the same time as gallbladder surgery is safe and practical. Ovarian cancer often starts in the fallopian tubes, so removing them may prevent it. The trial will enroll 240 women aged 35 and older to see if the extra procedur…

This study tests whether a single hypnosis session during chemotherapy can reduce anxiety and other side effects like nausea in young people with cancer. It includes 70 participants aged 15-49 with sarcoma, germ cell tumors, or breast cancer. Researchers will compare anxiety leve…

This pilot trial will test whether a prehabilitation program (exercise, protein drinks, breathing exercises, and coaching) is feasible for women awaiting ovarian cancer surgery. It compares in-person delivery, remote delivery via a web app, and standard education-only care. The s…

This study tests a web-based program designed to help advanced cancer patients manage symptoms like depression, pain, fatigue, and sleep problems, while also supporting their caregivers. The program combines online tools with guidance from healthcare professionals. Researchers wi…

This study compares two types of prehabilitation (exercise, nutrition, and psychological support) for 225 women with advanced ovarian cancer. One group starts prehab early during chemotherapy, while the other starts just before surgery. The goal is to see if early prehab reduces …

This phase III trial tests a therapy called CALM-TF for women with advanced ovarian cancer who experience traumatic stress. 300 participants will either receive 3-6 sessions of this trauma-focused therapy or standard care. Researchers will measure stress, depression, and quality …

This study looks at whether hand and foot exercises can reduce nerve pain (numbness, tingling) and improve quality of life in adults aged 65+ with gynecological cancer who are on chemotherapy. About 74 participants will do these exercises to see if they help with chemotherapy sid…

This study tests a Traditional Chinese Medicine (TCM) regimen to help ovarian cancer patients with common symptoms like trouble sleeping, fatigue, sadness, and distress. About 316 participants will receive either the TCM regimen or a placebo to see if it improves these symptoms. …

This study is testing a new questionnaire (called the QLQ-OV39) to see how well it measures quality of life in people with ovarian cancer. About 50 adults with early or advanced ovarian cancer will fill out the questionnaire and give feedback. The goal is to make sure the questio…

This study looks at whether an educational video can help people with certain cancers make informed choices about genetic testing. Participants will take a survey, watch a short video, and then take another survey to see if their knowledge and attitudes changed. The goal is to se…

This study tests whether a standardized ultrasound approach can reliably classify how ovarian cancer involves the liver area before surgery. Researchers will compare ultrasound images with what surgeons actually find during operations, using tissue samples as an extra check when …

This study examines tumor samples from 320 Latin American women with advanced ovarian, fallopian tube, or peritoneal cancer to describe the presence of certain markers (FRα, HER2, PD-L1, HRD, and BRCA). Researchers will collect medical history and test archived tumor tissue to se…

This study aims to create new laboratory models of ovarian cancer that no longer respond to standard platinum-based chemotherapy or PARP inhibitors. Researchers will take tumor tissue from patients with resistant disease and grow it in mice and in the lab to mimic real clinical c…

This study follows women aged 70 and older with ovarian cancer to understand why some experience cognitive decline or delirium during treatment. Researchers will track memory, thinking skills, frailty, and quality of life over 12 months, and analyze blood samples for markers of b…

This study will include about 2,748 people with breast, gynecologic, or pancreatic cancer. Researchers want to see if adding patient-reported outcomes—like symptoms, preferences, and travel distance—to tumor board discussions helps doctors make better treatment decisions. The goa…

This study will develop and test a free, cloud-based platform to educate women aged 18-45 with early-stage gynecologic cancer about fertility preservation options. Researchers will compare awareness, knowledge, and attitudes between a group using the platform and a group receivin…

This study looks at how doctors in tumor board meetings work together when discussing ovarian and uterine cancer cases. About 400 physicians will fill out surveys after each meeting to measure things like communication, teamwork, and decision-making. The goal is to understand wha…

This study tests whether a dye called indocyanine green can help surgeons find cancer spread in early ovarian cancer. About 30 women will receive the dye during surgery to see if it can identify affected lymph nodes. If it works, it may reduce the need for removing many lymph nod…

This early-stage study looks at whether taking oral paclitaxel with encequidar on an empty stomach or after a meal changes how much drug gets into the body. About 46 adults with advanced solid tumors (like breast, lung, or stomach cancer) will take the drugs in different sequence…

This study looks at whether a blood test can predict how well certain cancer drugs (PARP inhibitors) work in people with advanced breast, prostate, ovarian, or pancreatic cancer. Researchers will collect blood and tumor samples from 300 adults to analyze cancer cells and their DN…

This study follows 2100 women under 55 who had a hysterectomy, some with fallopian tube removal and some without. Researchers want to see if removing the tubes leads to earlier menopause. Participants will collect a few drops of blood at home and answer online questionnaires twic…

This study looks at how well different methods—imaging, a small camera surgery (laparoscopy), and open surgery (laparotomy)—agree on whether an ovarian mass can be completely removed. It will involve 28 women with primary ovarian cancer. The goal is to see if less invasive method…

This study uses a special 3D ultrasound to look at blood flow inside cervical and ovarian tumors. Researchers want to see if blood flow patterns can help tell the difference between cancer and pre-cancer, and if they can predict how well patients will do over time. About 100 adul…

This study checks if surgeons can tell key details about ovarian cancer by looking at images from a camera inside the belly. About 70-80 surgeons will review pictures from 19 patients and guess the cancer type and growth pattern. The goal is to see if visual clues can help plan t…

This study tests whether removing a larger piece of the pelvic lining during surgery can find tiny cancer deposits that standard biopsies might miss. About 390 adults with early-stage ovarian or fallopian tube cancer will undergo this procedure. The goal is to improve staging acc…

This study examines if different eating patterns, especially low-carbohydrate diets, are linked to better outcomes in women with high-grade serous ovarian cancer who are on maintenance therapy with PARP inhibitors. Researchers will review medical records and survey 600 patients f…

This study looks at how well patients do after surgery that removes both advanced gynecologic cancers and the major blood vessels they have grown into. Researchers will track 130 participants for up to 5 years to see survival rates and how long it takes for the cancer to return. …

This study looks back at the medical records of 200 people treated for gynecological cancers (like ovarian, cervical, or uterine cancer) at Assiut University Hospital between 2022 and 2025. The goal is to measure how long patients survive after diagnosis and compare those numbers…